Open AccessRole of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma
Author(s) -
Hamid Ehsan,
Ahsan Wahab,
Zunairah Shah,
Muhammad Khawar Sana,
Adeel Masood,
Abdul Rafae,
Hamza Hashmi
Publication year - 2021
Publication title -
journal of hematology
Language(s) - English
Resource type - Journals
eISSN - 1927-1220
pISSN - 1927-1212
DOI - 10.14740/jh844
Subject(s) - venetoclax , medicine , multiple myeloma , refractory (planetary science) , oncology , leukemia , biology , chronic lymphocytic leukemia , astrobiology
Biomarker-driven targeted therapies have been an area of exploration for innovative therapeutic options in oncology. B-cell lymphoma-2 (BCL-2) protein is an anti-apoptotic protein expressed on the clonal plasma cells in patients with multiple myeloma (MM). MM subsets with t (11;14) have overexpression of BCL-2 and can benefit from venetoclax (VEN) when used either alone or in combination with other chemotherapeutic agents with an overall response rate (ORR) ranging from 40% to 100%. The most commonly reported grade ≥ 3 adverse effects include cytopenias and gastrointestinal side effects. This review highlights the meaningful efficacy and tolerable safety of VEN monotherapy and its combination regimens in the treatment of relapsed refractory MM.